Rifaximin — Compare Prices at US & Canada Pharmacies

• Xifaxan, which contains the antibiotic rifaximin, is prescribed to treat traveler's diarrhea, irritable bowel syndrome with diarrhea (IBS-D), and to reduce the risk of overt hepatic encephalopathy in patients with severe liver disease.
• Uninsured patients typically pay around $70 per tablet, with total out-of-pocket costs ranging from approximately $421 for a three-day traveler's diarrhea course to several thousand dollars for longer IBS-D or hepatic encephalopathy treatment.
• No generic version of rifaximin is currently available in the US; approval for generic formulations is not expected before 2029.
• Financial relief options for patients without insurance include manufacturer copay assistance programs, patient assistance initiatives, and comparing prices across different pharmacies.

Xifaxan is a prescription antibiotic medication containing rifaximin as its active ingredient. It is indicated for three primary conditions: traveler's diarrhea, irritable bowel syndrome with diarrhea (IBS-D), and prevention of overt hepatic encephalopathy (OHE), a serious complication affecting patients with advanced liver disease. Because Xifaxan lacks a generic equivalent in the United States, patients without insurance face substantial costs—typically $70 per tablet. The total expense for a complete course varies significantly based on the condition being treated and the duration of therapy required. However, several strategies exist to help manage the financial burden.

Retail prices for Xifaxan average approximately $70 per tablet, translating to roughly $421 for a six-tablet supply. The total cost a patient incurs depends entirely on their prescribed regimen. A three-day course for traveler's diarrhea requires two tablets daily, or six tablets total. Treatment for IBS-D extends over 14 days with three tablets daily, necessitating 42 tablets and substantially higher expenses. Hepatic encephalopathy therapy does not follow a fixed timeline; patients typically require ongoing treatment for an extended period.

Less expensive alternatives exist, though their appropriateness depends on the specific diagnosis. For IBS-D treatment, Xifaxan addresses the underlying cause—bacterial overgrowth or imbalance in the intestines—whereas alternative medications such as antidiarrheals, anticholinergics, or serotonin antagonists merely suppress symptoms while remaining more affordable. Patients with traveler's diarrhea or hepatic encephalopathy may consider other antimicrobial agents; generic options like azithromycin represent the standard choice for traveler's diarrhea in cost-conscious treatment. For hepatic encephalopathy prevention in patients with recurrent episodes, Xifaxan remains the preferred option because alternative systemic antimicrobials carry higher risks of adverse effects and drug interactions. Any decision to pursue alternative treatments should involve consultation with the prescribing physician.

Currently, no generic version of Xifaxan is available in the United States. The earliest anticipated approval date for a generic rifaximin formulation is 2029.

Xifaxan functions by directly targeting the bacteria responsible for diarrhea, whereas antidiarrheal agents such as loperamide provide symptomatic relief without addressing the underlying bacterial cause. Many antidiarrheal medications are available in generic form, making them considerably less expensive treatment options for patients prioritizing affordability over bacterial eradication.

Comparison of Xifaxan and related medications:

Drug | Typical retail price | Cost-saving options Xifaxan 550 mg | $421 per 6 tablets | Manufacturer assistance, pharmacy price comparison Viberzi | $2,038 per 60 tablets | $1,462 per 60 tablets (brand-name discount pricing) Alosetron generic | $1,492 per 60 tablets | $70 per 60 tablets (generic pricing) Loperamide generic | $40 per 30 capsules | $12 per 30 capsules (generic pricing) Lomotil (diphenoxylate-atropine) | $130 per 30 tablets | $12 per 30 tablets (brand/generic options)

Note: Medication prices fluctuate regularly based on pharmacy, location, and market conditions. The prices listed represent typical retail rates at publication and may change. Brand-name pricing reflects full retail cost unless otherwise noted; generic alternatives are shown where available. Consult current pharmacy listings for the most up-to-date pricing in your area.

Xifaxan is manufactured in two dosage strengths, each carrying different per-unit costs. However, the total out-of-pocket expense depends more on the treatment duration than on the individual tablet price. A three-day traveler's diarrhea regimen differs dramatically in total cost from a 14-day IBS-D course or indefinite hepatic encephalopathy maintenance therapy.

Xifaxan pricing by strength:

Dosage strength | Typical scenario and tablet count | Estimated retail cost range 200 mg | Traveler's diarrhea (9 tablets, 3-day course) | Approximately $630 550 mg | IBS-D or hepatic encephalopathy (42 tablets, 14-day course or longer) | Several thousand dollars

For current retail pricing without insurance coverage, contact individual pharmacies or use online pharmacy price-comparison tools to identify the most competitive rates in your area.

Most major health insurance plans—including Medicare Part D and Medicaid—provide coverage for Xifaxan, though the extent and terms of coverage vary by plan. Some insurers require prescriptions to be filled through mail-order pharmacy services rather than retail locations.

Insurance approval for Xifaxan often requires additional steps beyond simple prescription submission. Carriers typically impose prior authorization requirements, which necessitate the prescribing physician documenting medical necessity, and quantity limits on the amount dispensed per billing period. If an insurance company initially denies coverage, it is often worthwhile to review the prescription details. Xifaxan is sometimes prescribed off-label for conditions such as C. difficile-associated diarrhea, and insurers frequently reject claims for non-FDA-approved uses. In such cases, patients may petition for a formulary exception, a process requiring the healthcare provider to submit a letter to the insurance company outlining the clinical justification for the prescription.

Purchasing Xifaxan at its full retail price presents a significant financial challenge for uninsured patients. Even those with insurance may face substantial copayments and out-of-pocket costs. The drug's manufacturer provides financial assistance through both a copay reduction card and a patient assistance program; however, these programs typically have strict income and eligibility requirements that exclude many uninsured individuals. Several more reliable cost-reduction strategies are available.

Various prescription discount programs and coupons are available to help reduce Xifaxan's cost. Discounts vary significantly by pharmacy and geographic location, so comparing prices across multiple local pharmacies can yield meaningful savings. Free discount cards and coupon programs can reduce the cost; for example, the price for 9, 200 mg tablets of Xifaxan may be as low as $101.

Significant price variation exists among different pharmacy chains and independent dispensaries for the same Xifaxan prescription. By purchasing Xifaxan at the lowest price available, patients can save almost $40 off the highest pharmacy price for six tablets. Investing time to phone nearby pharmacies or use online price-comparison tools can help identify the most affordable option before filling the prescription.

Many conditions treated with Xifaxan have alternative therapeutic options worth exploring. These may include different antibiotic agents, antidiarrheal medications, or other antimicrobial treatments. While such alternatives typically carry lower price tags, they often involve trade-offs—for instance, treating symptoms rather than root causes, or carrying different side effect profiles. A thorough discussion with your healthcare provider about both the clinical benefits and financial implications of various treatment paths can help identify the most suitable option for your circumstances.